Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Miller

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Journal of Neuroimmunology|November 5, 2003
The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-betaSarah Shapiro, Yanina Galboiz, Nitza Lahat, et al.
Journal of Autoimmunity|December 24, 2013
Genetic basis of myasthenia gravis - a comprehensive reviewNili Avidan, Rozen Le Panse, Sonia Berrih-Aknin, et al.
Journal of the Neurological Sciences|December 6, 2011
Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosisLena Melamud, Daniel Golan, Rafael Luboshitzky, et al.
Journal of the Neurological Sciences|December 14, 2002
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitisSarah Shapiro, Ariel Miller, Nitza Lahat, et al.
European Neurology|June 9, 2005
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's diseaseMichael Inspector, Judith Aharon-Perez, Lea Glass-Marmor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 24, 2006
Chronotherapy using corticosteroids for multiple sclerosis relapsesLea Glass-Marmor, Tamar Paperna, Yaara Ben-Yosef, et al.
International Journal of Molecular Sciences|May 4, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) TreatmentsElsebeth Staun-Ram, Anat Volkowich, Lea Glass-Marmor, et al.
Drug News & Perspectives|April 5, 2003
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a ModelIris Kirstein-Grossman, Jacques S. Beckmann, Doron Lancet, et al.
Multiple Sclerosis International|November 19, 2011
Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcareIzabella Lejbkowicz, Tamar Paperna, Nili Stein, et al.
Journal of Neuroimmunology|May 12, 2005
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cellsMichal Abraham, Sarah Shapiro, Arnon Karni, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Journal of Neuroimmunology|November 5, 2003
The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-betaSarah Shapiro, Yanina Galboiz, Nitza Lahat, et al.
Journal of Autoimmunity|December 24, 2013
Genetic basis of myasthenia gravis - a comprehensive reviewNili Avidan, Rozen Le Panse, Sonia Berrih-Aknin, et al.
Journal of the Neurological Sciences|December 6, 2011
Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosisLena Melamud, Daniel Golan, Rafael Luboshitzky, et al.
Journal of the Neurological Sciences|December 14, 2002
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitisSarah Shapiro, Ariel Miller, Nitza Lahat, et al.
European Neurology|June 9, 2005
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's diseaseMichael Inspector, Judith Aharon-Perez, Lea Glass-Marmor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 24, 2006
Chronotherapy using corticosteroids for multiple sclerosis relapsesLea Glass-Marmor, Tamar Paperna, Yaara Ben-Yosef, et al.
International Journal of Molecular Sciences|May 4, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) TreatmentsElsebeth Staun-Ram, Anat Volkowich, Lea Glass-Marmor, et al.
Drug News & Perspectives|April 5, 2003
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a ModelIris Kirstein-Grossman, Jacques S. Beckmann, Doron Lancet, et al.
Multiple Sclerosis International|November 19, 2011
Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcareIzabella Lejbkowicz, Tamar Paperna, Nili Stein, et al.
Journal of Neuroimmunology|May 12, 2005
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cellsMichal Abraham, Sarah Shapiro, Arnon Karni, et al.
Pageof 11